Chiesi breached Clause 7.2 over “3 steps per inhalation” claim in Fostair NEXThaler online ad (AUTH/2933/2/17)

📅 2017 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2933/2/17
PartiesHealth professional consultant to a pharmaceutical company (private complaint; Novartis named) v Chiesi Limited
ProductFostair (beclomethasone and formoterol), NEXThaler device
MaterialOnline/digital banner advertisement (ref CHNEX20161340 Dec 16) and related PI on Chiesi respiratory website
Main issue“Efficacy with only 3 steps per inhalation” claim vs SPC/PIL instructions; allegation of out-of-date PI (pneumonia warning)
Applicable Code year2016
Complaint received08 February 2017
Case completed02 May 2017
Breach clauses7.2
No breach clauses2, 4.1, 9.1
SanctionUndertaking received
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A health professional (consultant to Novartis, complaint made in a private capacity) complained about a Chiesi online banner advertisement for Fostair (beclomethasone/formoterol) NEXThaler (ref CHNEX20161340 Dec 16).
  • The ad included claims: “Efficacy with only 3 steps per inhalation” and “open – inhale – close”, and invited users to “See the features of the Fostair NEXThaler device”.
  • The complainant alleged the “3 steps” claim conflicted with the patient information leaflet (PIL) instructions (including breath-hold 5–10 seconds) and that prescribing information (PI) in the ad/website was out-of-date and omitted a pneumonia warning.
  • Chiesi said PI was current and included the pneumonia warning; it had been prepared in July 2016 ahead of MHRA approval of the SPC variation (5 September 2016) and used once the variation was approved.
  • Chiesi argued “3 steps” referred to the device operating sequence (open–inhale–close) and was supported by SPC headings and published literature.
⚖️

Outcome

  • Breach: Clause 7.2 (misleading claim) – the “3 steps per inhalation” claim was inconsistent with the SPC and PIL and therefore misleading.
  • No breach: Clause 4.1 – prescribing information for the online ad and the website was ruled up-to-date at the time of use.
  • No breach: Clause 9.1 – Panel did not consider the ad failed to maintain high standards.
  • No breach: Clause 2 – Panel did not consider the circumstances warranted particular censure.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training